ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0422

Greater Use of Assisted Reproductive Techniques but Comparable Obstetric Morbidity in a Population of Women with Spondyloarthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys

Sabrina Hamroun1, Grégoire Martin De Frémont2, Nathalie Costedoat-chalumeau3, Marion couderc4, René-Marc Flipo5, Jérémie Sellam6, Christophe Richez7, Rakiba Belkhir8, Laure Gossec9, Hubert Marotte10, Emmanuelle Dernis11, Aline Frazier12, Elisabeth Gervais13, Cedric Lukas14, Valerie Devauchelle15, Alban Deroux16, Véronique Le Guern17, Gaëlle Guettrot-Imbert18, Nathalie Lelong19, Camille Le Ray19, Raphaele Seror20 and Anna Molto21, and ENP 2021 and GR2 Study Groups, 1Cochin University Hospital, Paris, Ile-de-France, France, 2Le Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, Guyana, 3University Paris Cité, Paris, France, 4CHU de Clermont-Ferrand, Clermont-Ferrand, 5CHU Lille, Lille, Nord-Pas-de-Calais, France, 6Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France, 7Pellegrin Hospital, Rheumatology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Bordeaux, France, 8Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, 9Sorbonne Université, Paris, France, 10Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, 11CH LE MANS, LE MANS, Pays de la Loire, France, 12Lariboisière University Hospital, Paris, France, 13University hospital, Poitiers, France, 14Rheumatology department, CHU Montpellier, Montpellier, France, 15UBO, Brest, France, 16Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, 17APHP, Hôpital Cochin, Paris, 18Cochin Hospital, Paris, France, 19University of Paris, INSERM Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Paris, France, 20Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 21Groupe Hospitalier Cochin, AP-HP, Paris, France

Meeting: ACR Convergence 2024

Keywords: Cohort Study, pregnancy, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Spondyloarthritis (SpA) regularly affects women of childbearing age1. A higher obstetric morbidity in women with SpA is suggested in the literature in several countries, but no comparison between SpA patients and women in the general population is available for France. Furthermore, there is very few data on fertility in SpA patients. The aim of the study was to compare use of medically assisted reproduction and adverse fetal, maternal and pregnancy outcomes in women with SpA with matched controls from the French general population.

Methods: We conducted a matched comparative study of SpA patients included in the GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) national multicentre cohort from 2014 to June 2021 and controls from the French general population included in the French national perinatal surveys (Enquête Nationale Périnatale)2. The latter is a national survey carried out for one week every 5 years and recording around 13 000 births. As births before 22 gestational week (GW) and birth weights < 500 grams were excluded from the French national perinatal survey, the same exclusion criteria were applied to women with SpA from the GR2 cohort. Each pregnancy in patients with SpA was matched to 4 pregnancies in controls on age group (≤ 29, 30-34, 35-39, or ≥ 40 years), parity, area of residence, and gemellity. These matching variables were chosen according to their association with adverse pregnancy outcomes (potential confounders). Births in the GR2 cohort between 2015 and 2018 were matched to births in the 2016 survey and those between 2019 and 2021 were matched to births in the 2021 survey. RStudio’s MatchIt package was used to match SpA patients to controls. The frequency of each adverse pregnancy outcome was compared between the two groups using Fisher’s exact test or Chi-2. Odds ratios (OR) and their 95% confidence intervals (CI) were calculated for each variable.

Results: Of the 126 SpA patients included in the GR2 cohort, 116 pregnancies were selected after excluding births before 22 GW and/or birth weight < 500 grams. They were matched with 464 control pregnancies from the French national perinatal survey (224 pregnancies from the 2016 survey and 240 from the 2021 survey). The mean age of SpA patients was 32.0 (+/- 4.1) years and 54.3% were nulliparous. 54.8% of them were treated with biologics during pregnancy. The use of assisted reproductive techniques was higher in women with SpA 12.9% versus 7.1% (OR 1.95 95% CI [1.02-3.76]). However, there was no significant difference between the two populations regarding preterm birth, gestational diabetes, fetal macrosomia, gravidic hypertension, low birth weight, severe postpartum hemorrhage, maternal or fetal transfer to intensive care unit or congenital malformation (Table 1).

Conclusion: Women with SpA in the GR2 cohort required assisted reproductive techniques more frequently than control women from the French general population. However, the obstetrical issues were comparable in this selected population of women who were mostly treated with TNF inhibitors during pregnancy. This study therefore provides useful information for improved management of women of childbearing age with spondyloarthritis.

Supporting image 1

Table 1. Matched comparative analysis of use of assisted reproductive techniques and adverse fetal, maternal and pregnancy outcomes in SpA patients (GR2 cohort) and control women of the French general population (2016 and 2021 French national perinatal surveys).


Disclosures: S. Hamroun: None; G. Martin De Frémont: None; N. Costedoat-chalumeau: Bristol-Myers Squibb(BMS), 1; M. couderc: None; R. Flipo: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 2, Eli-Lilly, 2, Fresenius kabi, 7, Galapagos, 7, Janssen-Cilag, 2, Lilly, 7, Medac, 7, MSD, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Roche-Chugaï, 2, Sandoz, 2; J. Sellam: AbbVie/Abbott, 7, Bristol-Myers Squibb(BMS), 7, Fresenus kabi, 7, Galapagos, 7, Grunenthal, 7, MSD, 7, Nordic Pharma, 7, Novartis, 7, Pfizer, 7; C. Richez: None; R. Belkhir: None; L. Gossec: AbbVie, 2, 5, Amgen, 2, Biogen, 5, Bristol-Myers Squibb (BMS), 2, Celltrion, 2, Eli Lilly, 2, 5, Galapagos, 2, Janssen, 2, MSD, 2, Novartis, 2, 5, Pfizer, 2, Sandoz, 2, UCB, 2, 5; H. Marotte: AbbVie/Abbott, 4, 5, 6, Biogen, 5, 6, Bristol-Myers Squibb(BMS), 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Fresenius Kabi, 5, 6, Galapagos, 5, 6, Janssen, 5, 6, Merck/MSD, 5, 6, Nordic Pharma, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sanofi, 5, 6; E. Dernis: AbbVie/Abbott, 2, Amgen, 2, Boehringer-Ingelheim, 2, Celgene, 2, Eli Lilly, 2, Galapagos, 2, Gilead, 2, Janssen, 2, Merck/MSD, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Roche, 2, roche-chugaï, 2, Sandoz, 2, Sanofi, 2, UCB, 2; A. Frazier: None; E. Gervais: None; C. Lukas: None; V. Devauchelle: AbbVie, 2, BMS, 2, 5, Chugai, 5, Galapagos, 2, Janssen, 2, Lilly, 2, 5, Novartis, 2, Pfizer, 2; A. Deroux: None; V. Le Guern: None; G. Guettrot-Imbert: None; N. Lelong: None; C. Le Ray: None; R. Seror: Amgen, 6, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Pfizer, 6, Roche, 6; A. Molto: AbbVie, 2, 5, MSD, 2, 5, Pfizer, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Hamroun S, Martin De Frémont G, Costedoat-chalumeau N, couderc M, Flipo R, Sellam J, Richez C, Belkhir R, Gossec L, Marotte H, Dernis E, Frazier A, Gervais E, Lukas C, Devauchelle V, Deroux A, Le Guern V, Guettrot-Imbert G, Lelong N, Le Ray C, Seror R, Molto A. Greater Use of Assisted Reproductive Techniques but Comparable Obstetric Morbidity in a Population of Women with Spondyloarthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/greater-use-of-assisted-reproductive-techniques-but-comparable-obstetric-morbidity-in-a-population-of-women-with-spondyloarthritis-a-matched-comparative-analysis-of-the-gr2-prospective-cohort-and-the/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/greater-use-of-assisted-reproductive-techniques-but-comparable-obstetric-morbidity-in-a-population-of-women-with-spondyloarthritis-a-matched-comparative-analysis-of-the-gr2-prospective-cohort-and-the/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology